FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285403931> ?p ?o ?g. }

• W4285403931 endingPage "154330" @default.
• W4285403931 startingPage "154330" @default.
• W4285403931 abstract "The traditional Chinese medicine Gusuibu, the rhizome of Rhizoma Drynariae, is used to treat rheumatism and fractures. Naringenin (NAR) is an active ingredient in Gusuibu and has significant anti-inflammatory and antioxidant effects. However, the role of naringenin in iron overload-induced osteoarthritis (IOOA) is unknown.NAR reduces cartilage damage in IOOA.The effects of NAR on the viability of IOOA chondrocytes and the synthesis ability of type II collagen were evaluated using cell counting kit (CCK8) and toluidine blue assays. To determine the mechanism of action and characteristics of NAR, the intracellular iron ion content, apoptosis rate, and mitochondrial membrane potential (MMP) change, and malondialdehyde (MDA) levels, as well as the degree of reactive oxygen species (ROS) and lipid hydroperoxide (LPO) accumulation in the cells were detected in vitro and verified using western blotting and quantitative real-time PCR (qRT-PCR). To verify the role of NAR in vivo, IOOA mice were established using iron dextran and surgery-induced destabilised medial meniscus. Changes in the articular cartilage and subchondral bone were examined using Safranin O-fast Green staining (S-O), haematoxylin-eosin staining (H&E), and microcomputed tomography (μCT).In vitro, NAR attenuated the impairment of cell viability, apoptosis, and MMP caused by ferric ammonium citrate and interleukin-1β co-culture, increased the levels of MDA, reduced the expression of matrix metallopeptidase (MMP)3, MMP13, and Bax, and restored the expression of type II collagen (Col II). NAR showed a slight iron accumulation-reducing effect. NAR alleviated the accumulation of ROS and LPO in IOOA chondrocytes and upregulated antioxidant genes nuclear factor E2-related factor 2 (NRF2) and haem oxygenase 1 (HO-1). When ML385, a specific NRF-2 inhibitor, was added, the protective effect of NAR was significantly inhibited. In vivo, NAR reduced synovitis and attenuated cartilage damage and subchondral bone proliferation in IOOA mice.NAR can reduce oxidative stress through the NRF2-HO-1 pathway, alleviate cartilage damage under iron overload, and has the potential to treat IOOA." @default.
• W4285403931 created "2022-07-14" @default.
• W4285403931 creator A5006130318 @default.
• W4285403931 creator A5006822323 @default.
• W4285403931 creator A5014390459 @default.
• W4285403931 creator A5031245651 @default.
• W4285403931 creator A5049648860 @default.
• W4285403931 creator A5051826143 @default.
• W4285403931 creator A5056484501 @default.
• W4285403931 creator A5060010401 @default.
• W4285403931 creator A5060514920 @default.
• W4285403931 creator A5064461638 @default.
• W4285403931 creator A5085375811 @default.
• W4285403931 date "2022-10-01" @default.
• W4285403931 modified "2023-10-17" @default.
• W4285403931 title "Naringenin protects against iron overload-induced osteoarthritis by suppressing oxidative stress" @default.
• W4285403931 cites W1985004392 @default.
• W4285403931 cites W2026123588 @default.
• W4285403931 cites W2043362084 @default.
• W4285403931 cites W2055752218 @default.
• W4285403931 cites W2081951111 @default.
• W4285403931 cites W2082390213 @default.
• W4285403931 cites W2084209221 @default.
• W4285403931 cites W2099427592 @default.
• W4285403931 cites W2127955024 @default.
• W4285403931 cites W2167795966 @default.
• W4285403931 cites W2204004844 @default.
• W4285403931 cites W2206751744 @default.
• W4285403931 cites W2256257390 @default.
• W4285403931 cites W2265062179 @default.
• W4285403931 cites W2592384159 @default.
• W4285403931 cites W2600373563 @default.
• W4285403931 cites W2726121826 @default.
• W4285403931 cites W2743405616 @default.
• W4285403931 cites W2766726705 @default.
• W4285403931 cites W2898670022 @default.
• W4285403931 cites W2945806523 @default.
• W4285403931 cites W2954625654 @default.
• W4285403931 cites W2957373480 @default.
• W4285403931 cites W2968730769 @default.
• W4285403931 cites W2979799294 @default.
• W4285403931 cites W2989470675 @default.
• W4285403931 cites W2989826509 @default.
• W4285403931 cites W3017337165 @default.
• W4285403931 cites W3039656228 @default.
• W4285403931 cites W3039812257 @default.
• W4285403931 cites W3046034107 @default.
• W4285403931 cites W3107991803 @default.
• W4285403931 cites W3109937508 @default.
• W4285403931 cites W3112135797 @default.
• W4285403931 cites W3131445899 @default.
• W4285403931 cites W3157544230 @default.
• W4285403931 cites W3202718288 @default.
• W4285403931 cites W4213209557 @default.
• W4285403931 cites W4220903345 @default.
• W4285403931 doi "https://doi.org/10.1016/j.phymed.2022.154330" @default.
• W4285403931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35905566" @default.
• W4285403931 hasPublicationYear "2022" @default.
• W4285403931 type Work @default.
• W4285403931 citedByCount "7" @default.
• W4285403931 countsByYear W42854039312022 @default.
• W4285403931 countsByYear W42854039312023 @default.
• W4285403931 crossrefType "journal-article" @default.
• W4285403931 hasAuthorship W4285403931A5006130318 @default.
• W4285403931 hasAuthorship W4285403931A5006822323 @default.
• W4285403931 hasAuthorship W4285403931A5014390459 @default.
• W4285403931 hasAuthorship W4285403931A5031245651 @default.
• W4285403931 hasAuthorship W4285403931A5049648860 @default.
• W4285403931 hasAuthorship W4285403931A5051826143 @default.
• W4285403931 hasAuthorship W4285403931A5056484501 @default.
• W4285403931 hasAuthorship W4285403931A5060010401 @default.
• W4285403931 hasAuthorship W4285403931A5060514920 @default.
• W4285403931 hasAuthorship W4285403931A5064461638 @default.
• W4285403931 hasAuthorship W4285403931A5085375811 @default.
• W4285403931 hasConcept C153911025 @default.
• W4285403931 hasConcept C185592680 @default.
• W4285403931 hasConcept C190283241 @default.
• W4285403931 hasConcept C2776151105 @default.
• W4285403931 hasConcept C2776848411 @default.
• W4285403931 hasConcept C2778004101 @default.
• W4285403931 hasConcept C2779054382 @default.
• W4285403931 hasConcept C48349386 @default.
• W4285403931 hasConcept C53227056 @default.
• W4285403931 hasConcept C55493867 @default.
• W4285403931 hasConcept C71924100 @default.
• W4285403931 hasConcept C86803240 @default.
• W4285403931 hasConcept C98274493 @default.
• W4285403931 hasConceptScore W4285403931C153911025 @default.
• W4285403931 hasConceptScore W4285403931C185592680 @default.
• W4285403931 hasConceptScore W4285403931C190283241 @default.
• W4285403931 hasConceptScore W4285403931C2776151105 @default.
• W4285403931 hasConceptScore W4285403931C2776848411 @default.
• W4285403931 hasConceptScore W4285403931C2778004101 @default.
• W4285403931 hasConceptScore W4285403931C2779054382 @default.
• W4285403931 hasConceptScore W4285403931C48349386 @default.
• W4285403931 hasConceptScore W4285403931C53227056 @default.
• W4285403931 hasConceptScore W4285403931C55493867 @default.
• W4285403931 hasConceptScore W4285403931C71924100 @default.

• next